The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations

被引:20
作者
Beuther, David A. [1 ]
Murphy, Kevin R. [2 ]
Zeiger, Robert S. [3 ]
Wise, Robert A. [4 ]
McCann, William [5 ]
Reibman, Joan [6 ]
George, Maureen [7 ]
Gilbert, Ileen [8 ]
Eudicone, James M. [8 ]
Gandhi, Hitesh N. [8 ]
Ross, Melissa [9 ]
Coyne, Karin S. [9 ]
Chipps, Bradley [10 ]
机构
[1] Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA
[2] Boys Town Natl Res Hosp, Dept Pediat, Boys Town, NE USA
[3] Kaiser Permanente Bernard J Tyson Sch Med, Dept Clin Sci, Pasadena, CA USA
[4] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA
[5] Allergy Partners, Asheville, NC USA
[6] NYU, Sch Med, Dept Med, New York, NY USA
[7] Columbia Univ, Dept Nursing, New York, NY USA
[8] AstraZeneca, Wilmington, DE USA
[9] Evidera, Bethesda, MD USA
[10] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA
关键词
Asthma; Control; Uncontrolled; Impairment; Risk; Validation; Exacerbation; Questionnaire; Patient-reported outcome; COMMUNICATION INSTRUMENT; NATURAL-HISTORY; EPIDEMIOLOGY; VALIDATION; OUTCOMES; CHILDREN;
D O I
10.1016/j.jaip.2022.08.017
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: The Asthma Impairment and Risk Questionnaire (AIRQ) is a 10-item, equally weighted, yes/no con-trol tool validated in patients with asthma aged 12 years and older.OBJECTIVE: To evaluate AIRQ's ability to predict patient -reported exacerbations over 12 months.METHODS: Patients completed a baseline AIRQ during an in -person enrollment visit and reported exacerbations (ie, asthma -related courses of oral corticosteroids, emergency department/ urgent care visits, and hospitalizations) via monthly online sur-veys. Logistic regressions were performed using AIRQ control level (well-controlled [WC], not well-controlled [NWC], very poorly controlled [VPC]), age, sex, race, and body mass index as covariates and 1 or more and 2 or more exacerbations as the dependent variables (adjusted odds ratios [OR] and 95% Wald CIs). Kaplan-Meier analyses of time to first exacerbation by AIRQ control level were performed.RESULTS: A total of 1,112 patients were enrolled; 1,070 completed 1 or more surveys over 12 months (mean +/- SD 10.5 +/- 2.8 months); 70.5% female; age 43.9 +/- 19.3 years; 20.4% non-White; body mass index 30.6 +/- 8.7 kg/m2; AIRQ: WC 35.2%, NWC 38.1%, VPC 26.6%. A total of 45.7% of patients reported 1 or more exacerbations and 26.7% 2 or more exacerbations (WC 28.4% Z 1, 11.1% Z 2; NWC 46.3% Z 1,27.9% Z 2; VPC 67.7% Z 1, 45.6% Z 2). The ORs for 1 or more exac-erbations NWC versus WC were 2.1 (CI 1.6-2.9), and VPC versus WC were 4.6 (CI 3.3-6.5). The ORs for 2 or more exacerbations NWC versus WC were 3.1 (CI 2.1-4.6), and VPC versus WC were 6.1 (CI 4.0-9.1). Kaplan-Meier curves demonstrated clear differentiation of time to first exacerba-tion by AIRQ control level (P < .001).CONCLUSIONS: The AIRQ control level predicts exacerbation risk over 12 months and probability of time to first exacerbation.(c) 2022 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2022;10:3204-12)
引用
收藏
页码:3204 / +
页数:11
相关论文
共 22 条
  • [1] [Anonymous], 2007, NIH PUBLICATION
  • [2] AstraZeneca, ASTHM IMP RISK QUEST
  • [3] AstraZeneca, About us
  • [4] Evaluating construct validity of the Asthma Impairment and Risk Questionnaire using a 3-month exacerbation recall
    Chipps, Bradley E.
    Murphy, Kevin R.
    Wise, Robert A.
    McCann, William A.
    Beuther, David A.
    Reibman, Joan
    George, Maureen
    Gilbert, Ileen
    Eudicone, James M.
    Gandhi, Hitesh N.
    Harding, Gale
    Ross, Melissa
    Zeiger, Robert S.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (05) : 544 - +
  • [5] More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II
    Chipps, Bradley E.
    Haselkorn, Tmirah
    Paknis, Brandee
    Ortiz, Benjamin
    Bleecker, Eugene R.
    Kianifard, Farid
    Foreman, Aimee J.
    Szefler, Stanley J.
    Zeiger, Robert S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (05) : 1590 - +
  • [6] Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study
    Chipps, Bradley E.
    Zeiger, Robert S.
    Borish, Larry
    Wenzel, Sally E.
    Yegin, Ashley
    Hayden, Mary Lou
    Miller, Dave P.
    Bleecker, Eugene R.
    Simons, F. Estelle R.
    Szefler, Stanley J.
    Weiss, Scott T.
    Haselkorn, Tmirah
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 130 (02) : 332 - +
  • [7] Flesch R., 1951, TEST READABILITY
  • [8] Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN
  • [9] Examining the Reading Level of Internet Medical Information for Common Internal Medicine Diagnoses
    Hutchinson, Nora
    Baird, Grayson L.
    Garg, Megha
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (06) : 637 - 639
  • [10] Development and validation of a questionnaire to measure asthma control
    Juniper, EF
    O'Byrne, PM
    Guyatt, GH
    Ferrie, PJ
    King, DR
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (04) : 902 - 907